Crotamiton

For treating scabies, crotamiton should be applied to the whole body rather than a localized area. It is applied two or three times, with a 24-hour delay between applications, and the patient is asked to take a shower no sooner than after 48 hours. For children under 3 years, it is applied once daily. It can also be used to treat itching stemming from other causes, e.g. insect bites, in which case it is applied to the itching areas only, and repeated if necessary after 4 to 8 hours. Use near the eyes, or breaks in the skin, should be avoided. ==Pharmacology==

Crotamiton is toxic to the scabies mite. It probably acts as a general antipruritic by inhibition of TRPV4, a sensory ion channel that is expressed in the skin and primary sensory neurons. ==Pharmacokinetics==

After topical application, crotamiton is absorbed systemically. It has an elimination half-life of 30.9 hours and 4.8-8.8% is excreted in the urine. ==Side effects==

The most common side effect of crotamiton is skin irritation. ==Trade name==

Crotamiton is marketed under the trade names Eurax, which is manufactured by Ranbaxy Laboratories in the United States, and GlaxoSmithKline in the United Kingdom, and Euracin, which is manufactured by Green Cross in South Korea. In Germany, it is marketed under the brand name Crotamitex. In India, it is sold as Eurax by Ranbaxy Laboratories. == References ==